Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00094653
Status:
COMPLETED
Last Update Posted:
2011-07-11
First Post:
2004-10-21
Brief Title:
MDX-010 Antibody MDX-1379 Melanoma Vaccine or MDX-010MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Sponsor:
Organization:
Bristol-Myers Squibb
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
1783
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: